NO870476L - Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater. - Google Patents

Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater.

Info

Publication number
NO870476L
NO870476L NO87870476A NO870476A NO870476L NO 870476 L NO870476 L NO 870476L NO 87870476 A NO87870476 A NO 87870476A NO 870476 A NO870476 A NO 870476A NO 870476 L NO870476 L NO 870476L
Authority
NO
Norway
Prior art keywords
procedure
preparation
monoclonal antibody
human monoclonal
antibody preparations
Prior art date
Application number
NO87870476A
Other languages
English (en)
Other versions
NO870476D0 (no
NO176924C (no
NO176924B (no
Inventor
Howard V Raff
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of NO870476D0 publication Critical patent/NO870476D0/no
Publication of NO870476L publication Critical patent/NO870476L/no
Priority to NO941347A priority Critical patent/NO941347D0/no
Publication of NO176924B publication Critical patent/NO176924B/no
Publication of NO176924C publication Critical patent/NO176924C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO870476A 1986-02-07 1987-02-06 Antistoffpreparat til ikke-terapeutisk anvendelse NO176924C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO941347A NO941347D0 (no) 1986-02-07 1994-04-14 Fremgangsmåte for fremstilling av et humant monoklonalt antistoff

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82800586A 1986-02-07 1986-02-07
US94449586A 1986-12-19 1986-12-19

Publications (4)

Publication Number Publication Date
NO870476D0 NO870476D0 (no) 1987-02-06
NO870476L true NO870476L (no) 1987-08-10
NO176924B NO176924B (no) 1995-03-13
NO176924C NO176924C (no) 1995-06-21

Family

ID=27125154

Family Applications (1)

Application Number Title Priority Date Filing Date
NO870476A NO176924C (no) 1986-02-07 1987-02-06 Antistoffpreparat til ikke-terapeutisk anvendelse

Country Status (28)

Country Link
US (2) US5717071A (no)
JP (1) JP2645343B2 (no)
KR (1) KR870007697A (no)
CN (1) CN87102167A (no)
AT (1) AT398781B (no)
BE (1) BE1000967A5 (no)
CA (1) CA1339013C (no)
CH (1) CH672072A5 (no)
DE (1) DE3703711A1 (no)
DK (1) DK63187A (no)
ES (1) ES2009140A6 (no)
FI (1) FI94489C (no)
FR (1) FR2595946B1 (no)
GB (1) GB2186592B (no)
GR (1) GR870194B (no)
HK (1) HK21795A (no)
HU (1) HU203583B (no)
IE (1) IE59627B1 (no)
IL (1) IL81370A (no)
IT (1) IT1207589B (no)
LU (1) LU86761A1 (no)
MX (1) MX9203629A (no)
NL (1) NL8700286A (no)
NO (1) NO176924C (no)
NZ (2) NZ219187A (no)
OA (1) OA08477A (no)
PT (1) PT84258B (no)
SE (1) SE468747B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
DE3925161A1 (de) * 1989-03-15 1990-09-27 Boehringer Mannheim Gmbh Monoklonale, gegen eca gerichtete antikoerper und ihre verwendung
JPH0329196A (ja) * 1989-05-09 1991-02-07 Advanced Micro Devicds Inc センス増幅器
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
EP0635132B2 (en) * 1992-03-19 2008-05-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Broadly reactive opsonic antibodies that react with common staphylococcal antigens
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
ATE474849T1 (de) * 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
CA2694466A1 (en) * 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
US8444983B2 (en) * 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
BR112013013702A2 (pt) 2010-12-03 2016-09-13 Sanofi Pasteur Ltd composição para imunização contra streptococcus pneumoniae
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
KR102697723B1 (ko) 2017-01-18 2024-08-21 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
WO2021203024A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
CA1262238C (en) * 1982-09-30 1989-10-10 HUMAN MONOCLONAL ANTIBODIES AGAINST BACTERIAL TOXINS
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus

Also Published As

Publication number Publication date
ES2009140A6 (es) 1989-09-01
IE870320L (en) 1987-08-07
NZ219187A (en) 1990-12-21
NO870476D0 (no) 1987-02-06
CN87102167A (zh) 1988-02-03
FI94489C (fi) 1995-09-25
HUT46062A (en) 1988-09-28
PT84258A (en) 1987-03-01
NO176924C (no) 1995-06-21
FI94489B (fi) 1995-06-15
IL81370A (en) 1991-06-30
IL81370A0 (en) 1987-08-31
HK21795A (en) 1995-02-24
FR2595946A1 (fr) 1987-09-25
DE3703711A1 (de) 1987-09-24
US5837541A (en) 1998-11-17
JPS62270535A (ja) 1987-11-24
CA1339013C (en) 1997-03-25
CH672072A5 (no) 1989-10-31
DK63187D0 (da) 1987-02-06
LU86761A1 (fr) 1987-09-15
DK63187A (da) 1987-08-08
NZ233920A (en) 1990-12-21
DE3703711C2 (no) 1993-06-24
IE59627B1 (en) 1994-03-09
IT1207589B (it) 1989-05-25
SE8700467D0 (sv) 1987-02-06
NL8700286A (nl) 1987-09-01
GB2186592B (en) 1990-08-01
KR870007697A (ko) 1987-09-21
HU203583B (en) 1991-08-28
GB8702689D0 (en) 1987-03-11
FI870502A (fi) 1987-08-08
JP2645343B2 (ja) 1997-08-25
GB2186592A (en) 1987-08-19
FR2595946B1 (fr) 1991-10-04
OA08477A (fr) 1988-07-29
ATA26287A (de) 1994-06-15
IT8719292A0 (it) 1987-02-06
BE1000967A5 (fr) 1989-05-30
SE8700467L (sv) 1987-08-08
GR870194B (en) 1987-06-10
MX9203629A (es) 1992-07-01
AT398781B (de) 1995-01-25
SE468747B (sv) 1993-03-15
FI870502A0 (fi) 1987-02-06
PT84258B (pt) 1989-09-14
NO176924B (no) 1995-03-13
US5717071A (en) 1998-02-10

Similar Documents

Publication Publication Date Title
NO154905C (no) Fremgangsmaate for fremstilling av preparater for behandling av melanomer.
NO872966D0 (no) Fremgangsmaate for fremstilling av granulocyttstimulerende preparater.
NO870476L (no) Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater.
NO864971L (no) Fremgangsmaate for fremstilling av monoklonale antistoffer som er kryssbeskyttende overfor p. aeruginosaserotyper.
IT1197431B (it) Antigene anti-malarico, procedimento per la sua preparazione e vaccino che lo contiene
NO910209D0 (no) Fremgangsmaate for fremstilling av rekombinante humane anti-cd18 antistoffer.
NO885454L (no) Fremgangsmaate for fremstilling av triklormonosilan.
NO894210L (no) Fremgangsmaate for fremstilling av kinolyloxazol-2-oner.
NO894649D0 (no) Fremgangsmaate for fremstilling av (s)-alfa-ethyl-2-oxo-1-pyrrolidinacetamid.
NO895032L (no) Fremgangsmaate for fremstilling av 2-benzotiazoliner.
NO893794L (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO874200L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO890159D0 (no) Fremgangsmaate for fremstilling av 1-alkyl-5-nitroimidazoler.
DK69690D0 (da) Humane anti-rh(d) monoklonale antistoffer
IT8821300A0 (it) Procedimento di preparazione di morniflumato e analoghi.
DK69590D0 (da) Humane anti-rh(d) monoklonale antistoffer
NO871759L (no) Fremgangsmaate for fremstilling av sucralfatpreparater.
NO875359L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO873423D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO872233D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO895040D0 (no) Fremgangsmaate for fremstilling av polyhydroxybenzyloxypropanolaminer.
NO893796D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO893795L (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO873452L (no) Fremgangsmaate for fremstilling av galeniske preparater.
NO872633L (no) Monoklonalt antistoff mot humant plasminogen, samt fremstilling derav.